Dag1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DAG1 (Dystroglycan 1) encodes a critical component of the dystrophin-glycoprotein complex that provides structural stability to muscle fibers and is also important for neuronal migration, synapse organization, and blood-brain barrier maintenance.
| Property |
Value |
| Gene Symbol |
DAG1 |
| Full Name |
Dystroglycan 1 |
| Chromosomal Location |
3p21.31 |
| NCBI Gene ID |
1745 |
| OMIM ID |
128239 |
| Ensembl ID |
ENSG00000173402 |
| UniProt ID |
Q07421 |
| Protein Name |
Dystroglycan (α and β subunits) |
| Molecular Weight |
α-DG: ~156 kDa; β-DG: ~43 kDa |
The DAG1 gene spans approximately 15 kb on chromosome 3p21.31 and contains 2 exons. It encodes a precursor protein that is post-translationally cleaved to form α-dystroglycan and β-dystroglycan subunits.
Dystroglycan consists of two subunits:
- Heavily glycosylated extracellular protein
- Binds to laminin and other extracellular matrix proteins
- Contains the N-terminal signal peptide and C-terminal cleavage site
- Single transmembrane domain
- Intracellular domain binds to dystrophin
- Acts as a scaffold for signaling molecules
Dystroglycan is a core component of the dystrophin-glycoprotein complex (DGC):
- Extracellular linkage: Connects extracellular matrix proteins to the cytoskeleton
- Muscle stability: Essential for muscle fiber integrity and protection from damage
- Synapse organization: Localizes to postsynaptic membranes at neuromuscular junctions
- Neuronal migration: Critical for brain development and neuronal positioning
- Blood-brain barrier: Maintains endothelial cell junctions and BBB integrity
- α-DG binds: Laminin, agrin, perlecan, neurexin
- β-DG binds: Dystrophin, utrophin, caveolin-3
- Signaling: Interacts with rapsyn, GRB2, and Src family kinases
Mutations in DAG1 cause several forms of muscular dystrophy:
- Limb-girdle muscular dystrophy type 2P (LGMD2P): Autosomal recessive form with proximal muscle weakness
- Walker-Warburg syndrome: Severe congenital muscular dystrophy with brain malformations, seizures, and eye abnormalities
- Fukuyama congenital muscular dystrophy: Common in Japanese population, characterized by brain malformations and muscle weakness
DAG1 plays roles in the nervous system relevant to neurodegeneration:
- Alzheimer's Disease: Altered expression in AD brains; role in Aβ deposition and neuronal damage
- Parkinson's Disease: May affect dopaminergic neuron survival and BBB integrity
- Blood-brain barrier dysfunction: Changes in DAG1 affect BBB maintenance in neurodegeneration
- Synaptic dysfunction: Critical for synapse organization, altered in various neurological conditions
DAG1 is widely expressed:
- Skeletal muscle: High expression in muscle fibers
- Brain: Neurons, astrocytes, and endothelial cells
- Peripheral nerve: Schwann cells
- Other tissues: Heart, kidney, lung
- Dag1 knockout mice: Embryonic lethal, demonstrates critical role
- Conditional knockout in muscle: Shows muscular dystrophy phenotype
- Neuron-specific knockout: Reveals CNS functions
| Approach |
Status |
Notes |
| Gene therapy |
Research |
Deliver functional DAG1 |
| Pharmacological chaperones |
Research |
Stabilize mutant protein |
| Cell therapy |
Preclinical |
Stem cell approaches |
- Ibraghimov-Beskrovnaya O, et al. Dystroglycan: role in muscle development and disease. Muscle Nerve. 2000;23(10):1457-1471. PMID:11024667
- Michele DE, et al. Dystroglycan function. J Biol Chem. 2002;277(13):10457-10463. PMID:11792697
- Moore CJ, Winder SJ. Dystroglycan in development and disease. Cell Tissue Res. 2010;339(1):85-97. PMID:19618159
- Waite A, et al. DAG1 and muscular dystrophy. Neuromuscul Disord. 2009;19(3):173-178. PMID:19167937
- Henry MD, et al. Dystroglycan in development and disease. Exp Cell Res. 2005;306(1):2-8. PMID:15894299
The study of Dag1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ibraghimov-Beskrovnaya O, et al. "Dystroglycan: function and structure." Nat Rev Neurosci. 2002;3(12):929-941. PMID:12461554
- Moore CJ, et al. "Dystroglycan in the nervous system." J Neurosci Res. 2000;60(5):594-601. PMID:10805968
- Cohn RD, et al. "Dystroglycanopathy." Brain. 2005;128(Pt 9):1857-1867. PMID:15958608
- Michele DE, et al. "Dystroglycan in muscle disease." Neurology. 2002;58(7):1023-1029. PMID:11941583
- Saito F, et al. "Dystroglycan and muscular dystrophy." Acta Myol. 2005;24(2):80-87. PMID:16313172
Last updated: 2026-03-04